Lexical Diversity and Other Linguistic Measures in Schizophrenia Associations With Negative Symptoms and Neurocognitive Performance

被引:2
|
作者
Compton, Michael T. T. [1 ,2 ]
Ku, Benson S. S. [3 ]
Covington, Michael A. A. [4 ]
Metzger, Celia [5 ]
Hogoboom, Anya [5 ]
机构
[1] New York State Psychiat Inst & Hosp, 722 W 168th St, Room R249, New York, NY 10032 USA
[2] Columbia Univ, Vagelos Coll Phys & Surg, Dept Psychiat, New York, NY USA
[3] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA
[4] Univ Georgia, Inst Artificial Intelligence, Athens, GA USA
[5] William & Mary, Dept English, Linguist Program, Williamsburg, VA USA
关键词
Alogia; lexical diversity; psychosis; schizophrenia; type-token ratio; CONSENSUS COGNITIVE BATTERY; MINI-MENTAL-STATE; TOKEN RATIO; PART; LANGUAGE; RELIABILITY; SPEECH;
D O I
10.1097/NMD.0000000000001672
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Straightforward linguistic measures may be indicators of reduced language production and lexical diversity among individuals with schizophrenia with negative symptoms and neurocognitive impairments. We compared 98 patients with schizophrenia to 101 unaffected controls on six language variables (e.g., number of relationships between objects, use of complex transitions in the narrative structure), number of words produced, and lexical diversity computed as the moving average type-token ratio from both speaking and writing tasks. Patients differed from controls on nearly all of the linguistic measures; number of words produced had the strongest effect, with an average Cohen's d of 0.68; values pertaining to lexical diversity were 0.50 and 0.32, respectively, for the speaking tasks and the writing tasks. Most measures were correlated with alogia and other domains of negative symptoms (including avolition-apathy and anhedonia-asociality), as well as with diverse neurocognitive domains, especially those pertaining to working memory, verbal learning, and verbal category fluency. Further work is needed to understand longitudinal changes in these linguistic variables, as well as their utility as measures of alogia.
引用
收藏
页码:613 / 620
页数:8
相关论文
共 50 条
  • [21] Measures of reward responsiveness in animal models of negative symptoms of schizophrenia
    Markou, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 65 - 65
  • [22] Are insight measures related to other symptoms in first episode schizophrenia?
    Drake, RJ
    Haley, C
    Lewis, SW
    SCHIZOPHRENIA RESEARCH, 1998, 29 (1-2) : 34 - 34
  • [23] THE INCIDENCE OF NEGATIVE SYMPTOMS IN EARLY SCHIZOPHRENIA, MANIA AND OTHER PSYCHOSES
    MONTAGUE, LR
    TANTAM, D
    NEWBY, D
    THOMAS, P
    RING, N
    ACTA PSYCHIATRICA SCANDINAVICA, 1989, 79 (06) : 613 - 618
  • [24] THE FUNCTIONAL SIGNIFICANCE OF METACOGNITIVE CAPACITY IN SCHIZOPHRENIA: ASSOCIATIONS WITH NEGATIVE SYMPTOMS AND INSIGHT
    Lysaker, Paul
    Kukla, Marina
    Buck, Kelly
    Yanos, Philip
    SCHIZOPHRENIA BULLETIN, 2017, 43 : S36 - S36
  • [25] Cerebral white matter abnormalities and their associations with negative but not positive symptoms of schizophrenia
    Asami, Takeshi
    Lee, Sang Hyuk
    Bouix, Sylvain
    Rathi, Yogesh
    Whitford, Thomas J.
    Niznikiewicz, Margaret
    Nestor, Paul
    McCarley, Robert W.
    Shenton, Martha E.
    Kubicki, Marek
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2014, 222 (1-2) : 52 - 59
  • [26] Negative expectancy appraisals and defeatist performance beliefs and negative symptoms of schizophrenia
    Couture, Shannon M.
    Blanchard, Jack J.
    Bennett, Melanie E.
    PSYCHIATRY RESEARCH, 2011, 189 (01) : 43 - 48
  • [27] Does Integrated Neurocognitive Therapy (INT) reduce severe negative symptoms in schizophrenia outpatients?
    Mueller, Daniel R.
    Khalesi, Zahra
    Benzing, Valentin
    Castiglione, Clelia I.
    Roder, Volker
    SCHIZOPHRENIA RESEARCH, 2017, 188 : 92 - 97
  • [28] Structural white matter abnormalities in Schizophrenia and associations with neurocognitive performance and symptom severity
    Male, Alie G.
    Goudzwaard, Esther
    Nakahara, Soichiro
    Turner, Jessica A.
    Calhoun, Vince D.
    Mueller, Bryon A.
    Lim, Kelvin O.
    Bustillo, Juan R.
    Belger, Aysenil
    Voyvodic, James
    O'Leary, Daniel
    Mathalon, Daniel H.
    Ford, Judith M.
    Potkin, Steven G.
    Preda, Adrian
    van Erp, Theo G. M.
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2024, 342
  • [29] Proof-of-concept trial with the neurosterold pregnenolone targeting neurocognitive and negative symptoms in schizophrenia
    Marx, Christine E.
    Keefe, Richard S.
    Leimone, Linda A.
    Hamer, Robert M.
    Bradford, Daniel W.
    Dunn, Lawrence
    Payne, Victoria M.
    Naylor, Jennifer C.
    Savitz, Adam J.
    Strauss, Jennifer L.
    Lieberman, Jeffrey A.
    Shampine, Lawrence J.
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 13S - 13S
  • [30] POSITIVE AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - ATTENTIONAL PERFORMANCE CORRELATES
    WALKER, E
    HARVEY, P
    PSYCHOPATHOLOGY, 1986, 19 (06) : 294 - 302